Detail

Keywords

Clinical Medicine; Nuclear Medicine; Positron-Emission Tomography; Radiopharmaceuticals; Whole Body Imaging

Research interests

Keywords: Therarnostics--Oncology-Prostate Cancer-Neuroendocrine Tumors-Differentiated Thyroid Carcinoma-Precision Medicine-Emerging Tracers-Patiented Centered Outcomes

I work in clinical theranostics, a diagnostic-therapeutic approach in which imaging and therapy are directed at the same molecular targets. My focus is on radioligand therapies in prostate cancer, neuroendocrine tumors, and thyroid carcinoma. I am interested in how imaging, treatment indication, therapy delivery, and follow-up can be aligned to form coherent, patient-centered care pathways.

In clinical decision-making, my work emphasizes precision in therapy selection: choosing the right therapeutic intensity at the right time, for the right patient, based on biological behavior, imaging response, and tolerability.

I collaborate across nuclear medicine, oncology, urology, pathology, radiology, surgery and radiopharmacy, and in interdisciplinary tumor boards to ensure that treatment decisions are grounded in both evidence and the individual patient context.

A particular focus lies in the clinical translation of emerging theranostic tracers and in evaluating tolerability and patient-relevant outcomes.

My work aims to support the responsible and sustainable integration of theranostic therapies into routine care, guided by clinical quality and close interdisciplinary collaboration that actively incorporates expertise from all involved specialties.

Selected publications

1. Schmitl S*, Kretschmer-Chott E*, Patronas EM, Kramer G, Ritt P, Fuchs E, Weisbrod M, Nics L, Mitterhauser M, Hacker M. Efficacy, Safety, Blood Kinetics, and 213Bi Distribution Studies of [225Ac]Ac-SibuDAB in Prostate Cancer Patients. J Nucl Med. 2025;66(8):1239–1244. doi:10.2967/jnumed.125.269655. PMID: 40473466. (shared first authorship)
2. Melhorn P, Kretschmer-Chott E, Raderer M, Kiesewetter B. Comparisons of treatment performance and therapy sequences in neuroendocrine neoplasms using progression-free survival ratios. Eur J Nucl Med Mol Imaging. 2025 Jun 21.
3. Kraus T, Shengelia-de Lange N, Einspieler H, Hacker M, Haug A, Kretschmer-Chott E, Karanikas G. Value of follow-up diagnostic radioiodine scans in differentiated thyroid cancer. Endocr Connect. 2024 Apr 12.
4. Rasul S, Hartenbach M, Wollenweber T, Kretschmer-Chott E, et al. Clinical outcome of standardized Lu-PSMA-617 therapy in metastatic prostate cancer patients receiving 7400 MBq every 4 weeks. Eur J Nucl Med Mol Imaging. 2021.
5. Schmatz AI, Streubel B, Kretschmer-Chott E, et al. Primary follicular lymphoma of the duodenum Journal of Clinical Oncology. 2011